Kardigan, Inc. (KARD)
Market Closed
14 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
19. 05
+0.53
+2.8618%
$
1.93B Market Cap
- P/E Ratio
- Div Yield
806,572 Volume
- Eps
$ 18.52
Previous Close 
Want to track KARD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification
Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key clinical readouts before further funding is needed. Upcoming 2027 data from all three lead programs will be pivotal in validating KARD's hypotheses and informing future capital allocation.
Seekingalpha | 1 day ago
